Fig. 3From: Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrheaWeekly changes in BSFS scores. Line graph: means ± standard deviation. P values were calculated using the χ 2-test, as follows: ***P < 0.001, **P < 0.01, and *P < 0.05Back to article page